Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB

Trial Profile

Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs ABO-101 (Primary)
  • Indications Mucopolysaccharidosis III
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 07 Feb 2018 According to an Abeona Therapeutics media release, the company plans for additional enrollments following pending review by independent Data Safety Monitoring Board (DSMB).
    • 07 Feb 2018 Preliminary 30-Day safety and biopotency signals from the first patient dosed in this trial presented in an Abeona Therapeutics media release.
    • 20 Dec 2017 According to an Abeona Therapeutics media release, has been dosed in the trial, at Nationwide Children's Hospital, Columbus, Ohio.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top